Back
Blueprint Medicines Stock Price Chart
Top investors are buying this "unlisted" stock
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Sell
28
BPMC
Blueprint Medicines
Last Price:
$82.97
Seasonality Move:
7.42%
7 Day Trial
ALL ACCESS PASS
$
7
Mode Mobile Could be Next in Line
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.-
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BPMC is experiencing slight buying pressure.
Blueprint Medicines Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 81.74 | Buy |
| 20-day SMA: | 86.66 | Sell |
| 50-day SMA: | 92.91 | Sell |
| 200-day SMA: | 95.85 | Sell |
| 8-day EMA: | 82.51 | Buy |
| 20-day EMA: | 85.62 | Sell |
| 50-day EMA: | 90.34 | Sell |
| 200-day EMA: | 92.9 | Sell |
Blueprint Medicines Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -3.24 | Sell |
| Relative Strength Index (14 RSI): | 41.69 | Sell |
| Chaikin Money Flow: | 356409 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (82.94 - 91.7) | Sell |
| Bollinger Bands (100): | (86.04 - 103.74) | Sell |
Blueprint Medicines Technical Analysis
| Apr 1 | Apr 2 | Apr 3 | Apr 4 | Apr 7 | Apr 8 | Apr 9 | Apr 10 | Apr 11 | Apr 14 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 01 | 02 | 03 | 04 | 07 | 08 | 09 | 10 | 11 | 14 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 82.53 while BPMC 8-day simple moving average is 81.74, which is a Buy signal.
-
The stock price of BPMC is 82.53 while Blueprint Medicines 20-day SMA is 86.66, which makes it a Sell.
-
Blueprint Medicines 50-day simple moving average is 92.91 while BPMC share price is 82.53, making it a Sell technically.
-
BPMC stock price is 82.53 and Blueprint Medicines 200-day simple moving average is 95.85, creating a Sell signal.
BPMC Technical Analysis vs Fundamental Analysis
Sell
28
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $82.53. The Score for BPMC is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.
Blueprint Medicines Stock Info
Market Cap:
5.3B
Price in USD:
82.53
Share Volume:
775.5K
Blueprint Medicines 52-Week Range
52-Week High:
121.90
52-Week Low:
73.04
Sell
28
Blueprint Medicines (BPMC)
is a Sell
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 82.53 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 82.53 while BPMC 8-day exponential moving average is 82.51, which is a Buy signal.
-
The stock price of BPMC is 82.53 while Blueprint Medicines 20-day EMA is 85.62, which makes it a Sell.
-
Blueprint Medicines 50-day exponential moving average is 90.34 while BPMC share price is 82.53, making it a Sell technically.
-
BPMC stock price is 82.53 and Blueprint Medicines 200-day simple moving average is 92.90, creating a Sell signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings decrease this quarter of $0.62 per share, an increase next quarter of $0.07 per share, a decrease this year of $0.25 per share, and an increase next year of $2.68 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is -3.24, suggesting Blueprint Medicines is a Sell
-
Blueprint Medicines Relative Strength Index (RSI) is 41.69, which suggest Blueprint Medicines is oversold
-
The Bollinger Bands (25) for Blueprint Medicines is (82.94 - 91.7), which suggest Blueprint Medicines is a Sell
-
The Bollinger Bands (100) for Blueprint Medicines is (86.04 - 103.74), which suggest Blueprint Medicines is a Sell
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.